We recently proposed the existence of mGlu 3 -preferring autoreceptors in spinal cord terminals and of mGlu 2 -preferring autoreceptors in cortical terminals. This study aims to verify our previous conclusions and to extend their pharmacological characterization.
Introduction
The group II metabotropic glutamate (mGlu) receptors comprise mGlu 2 and mGlu 3 receptors. The high sequence homology of the two receptors for a long time limited the possibility of distinguishing the respective contribution of mGlu 2 and mGlu 3 units to the expression of native group II mGlu receptors in the CNS (Niswender and Conn, 2010; Nicoletti et al., 2011; . However, there is now evidence demonstrating that mGlu 2 and mGlu 3 receptors are differently expressed in particular CNS regions (Gu et al., 2008; Wright et al., 2013) and in cells (neurons and astrocytes; Ohishi et al., 1993; Tamaru et al., 2001; Copeland et al., 2017) and could have different roles in controlling synaptic transmission (Kew et al., 2002; Corti et al., 2007; Hanna et al., 2013; Sanger et al., 2013) . Altogether, these observations support the existence of group II mGlu receptor subtypes.
The recent discovery of new ligands able to separate the role of the two receptors has allowed the pharmacological characterization of the native mGlu 2/3 receptors. Consistently, we recently proposed the existence of presynaptic mGlu 3 -preferring autoreceptors in spinal cord glutamate terminals and presynaptic mGlu 2 -preferring autoreceptors in the cortex of adult mice (Di Prisco et al., 2016a) . These conclusions originated from the results obtained in release studies with N-acetyl-aspartyl-glutamate (NAAG), which has been shown to selectively activate the mGlu 3 receptor subtype (Neale et al., 2011; Romei et al., 2012; Di Prisco et al., 2016a) and LY541850, a selective mGlu 2 receptor agonist with mGlu 3 receptor antagonist activity Sanger et al., 2013) .
In this study we aimed to extend our previous work on the pharmacological characterization of the presynaptic mGlu 2/3 autoreceptors in cortical and spinal cord synaptosomes. We investigated the effects of LY566332 and BINA, two positive allosteric modulators (PAMs) of the mGlu 2 receptor subtype (Rorick-Kehn et al., 2005; Benneyworth et al., 2007; Molinaro et al., 2009; Caraci et al., 2011; Sanger et al., 2013) , and of LY2389575 and ML337, which are selective mGlu 3 receptor negative allosteric modulators (NAMs; Caraci et al., 2011; Wenthur et al., 2013) , on the LY379268-induced reduction of glutamate exocytosis from both synaptosomal preparations. To further characterize the respective contribution of mGlu 2 and mGlu 3 receptor proteins to the assembly of the mGlu 2/3 autoreceptors, we applied an unconventional immunological approach. Briefly, cortical and spinal cord synaptosomes were incubated with selective antibodies raised against the outer sequences of the mGlu 2 and the mGlu 3 receptor proteins in order to determine whether and to what extent these antibodies interfere with the LY379268-mediated inhibition of glutamate exocytosis. These antibodies were also used in Western blot and confocal microscopy analyses to demonstrate the expression of mGlu 3 and mGlu 2 receptors in spinal cord and cortical synaptosomes and to analyse their reciprocal localization. The results from functional and immunochemical studies confirm that the mGlu2/3 autoreceptors in spinal cord and cortical terminals differ one each other in terms of mGlu receptor composition and pharmacological profile.
Methods

Animal experiments
Mice (male, strain C57BL/6J) were obtained from Charles River (Calco, Italy) and were housed in the animal facility of DIFAR, Section of Pharmacology and Toxicology. mGlu 2 receptor knockout (mGlu2 À/À ) mice, mGlu 3 (Linden et al., 2005) and housed at IRCSS Neuromed. These mice were individually genotyped for the mGlu 2 and mGlu 3 receptor gene by PCR. All animals were kept under environmentally controlled conditions (ambient temperature = 22°C, humidity = 40%) on a 12 h light/dark cycle with food and water available ad libitum.
Mice were killed by cervical dislocation followed by decapitation and the cortex and/or the spinal cord rapidly removed. The experimental procedures were in accordance with the European legislation (European Communities Council Directive of 24 November 1986, 86/609/EEC) and were approved by the Italian Ministry of Health (DDL 26/2014 and previous legislation; protocol number no. 50/2011-B) . Experiments were performed following the Guidelines for Animal Care and Use of the National Institutes of Health. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) .
Sixty-two C57BL/6 mice were used in the release experiments with selective positive and negative allosteric modulators (39 mice) and with the anti-mGlu 2 and anti-mGlu 3 selective antibodies (23 mice). In line with the 3Rs rules (replacement, refinement and reduction), both cortical and spinal cord synaptosomes were prepared from each animal, and one preparation was used for release experiments, while the other one, for Western blot analyses or confocal microscopy. Nine genetically modified mice (mGlu2 À/À mice, mGlu3
À/À mice and mGlu2/3 À/À mice, three mice for each group) and three WT CD1 mice were used to confirm the specificity of anti-mGlu 2 and anti-mGlu 3 antibodies.
Preparation of synaptosomes
Mouse cortical and spinal cord purified synaptosomes were prepared as previously described (Musante et al., 2011) . Briefly, the tissue was homogenized in 10 volumes of 0.32 M sucrose, buffered to pH 7.4 with Tris-(hydroxymethyl)-amino methane (TRIS; final concentration 0.01 M) using a glass/Teflon tissue grinder (clearance 0.25 mm); the homogenate was centrifuged at 1000× g for 5 min to remove nuclei and debris, and the supernatant was gently stratified on a discontinuous Percoll gradient (6, 10 and 20% v . 
Release experiments
Synaptosomes were incubated for 15 min a 37°C in a rotary water bath in the presence of
f.c.: 50 nM). In order to study the impact of anti-mGlu antibodies on the LY379268-mediated inhibition of glutamate exocytosis, synaptosomes were incubated for 30 min in the presence of the following antibodies: polyclonal rabbit antimGlu 3 (1:1000) or monoclonal mouse anti-mGlu 2 (1:1000); in these experiments, the radioactive tracer was added at t = 15 min of incubation. Identical portions of the synaptosomal suspensions were layered on microporous filters at the bottom of parallel thermostated chambers in a Superfusion System (Raiteri et al., 1974 , Pittaluga, 2016 Ugo Basile, Comerio, Varese, Italy) . Synaptosomes were transiently (90 s) exposed, at t = 39 min, to high KCl-containing medium (12 mM KCl for cortical synaptosomes or 15 mM KCl for spinal cord synaptosomes, NaCl substituting for an equimolar concentration of KCl; Zucchini et al., 2013) in the absence or in the presence of the agonist LY379268. Allosteric modulators were always added concomitantly with the agonist. Fractions were collected as follows: two 3 min fractions (basal release), one before (t = 36-39 min) and one after (t = 45-48 min) a 6 min fraction (t = 39-45 min; evoked release).The collected fractions and the superfused synaptosomes were measured for radioactivity.
The amount of radioactivity released into each superfusate fraction was expressed as a percentage of the total radioactivity. The K + -evoked overflow was estimated by subtracting the neurotransmitter content in the first and the third fractions collected (basal release, b1 and b3) from that in the 6 min fraction collected during and after the depolarization pulse (evoked release, b2). 
Immunoblotting analysis
The cortical and spinal cord purified synaptosomes were lysed in ice-cold lysis buffer (150 mM NaCl, 50 mM Tris, 1% Triton X-100, protease inhibitors, pH 8.0) and quantified for protein content. Samples were boiled for 5 min at 95°C in SDS-PAGE loading buffer. Proteins were then separated by SDS 7.5% PAGE and transferred onto PVDF membranes. Membranes were incubated for 1 h at room temperature in Tris-buffered saline-Tween (t-TBS: 0.02 M Tris, 0.150 M NaCl and 0.05% Tween 20), containing 5% (w . v-1) non-fat dried milk and then probed with mouse monoclonal anti-mGlu 2 receptor antibody (1:1000 for cortical synaptosomes and 1:500 for spinal cord synaptosomes) or rabbit polyclonal anti-mGlu 3 receptor antibody (1:1000) and mouse anti-β-tubulin antibody (1:800) overnight at 4°C. After extensive washes in t-TBS, membranes were incubated for 1 h at room temperature with appropriate horseradish peroxidise-linked secondary antibodies (1:20 000).
In the experiments carried out to verify the specificity of the anti-mGlu 2 and anti-mGlu 3 antibodies, mouse cerebral cortices (from WT and knockout mice) were dissected out and homogenized at 4°C in Tris-HCl pH 7.5, 10 mM; NaCl, 150 mM; SDS 0.1%, EDTA, 5 mM and complete TM protease cocktail tablets. Proteins (20 μg) from supernatants were separated by 8% SDS-PAGE and transferred on immuno-blot PVDF membranes. Membranes were incubated with mouse anti-mGlu 2 (1:1000, 1 h at room temperature, in t-TBS), rabbit anti-mGlu 3 receptor (1:1000, 1 h at room temperature, in t-TBS) and mouse anti-β-tubulin (1:800, overnight at 4°C) antibodies and then for 1 h with the appropriate peroxidisecoupled secondary antibody. Immunoblots were visualized with an enhanced chemiluminescence plus Western blotting detection system. β-tubulin was used as an internal control.
Confocal microscopy and co-localization
Mouse cortical and spinal cord synaptosomes were fixed with 2% paraformaldehyde for 15 min, permeabilized with 0.05% Triton X-100 PBS for 5 min and incubated with the following primary antibodies: mouse anti-mGlu 2 receptor (1:1000), rabbit anti-mGlu 3 receptor (1:1000) and guinea pig antivesicular glutamate transporters type 1 (VGLUT1; 1:500). After extensive washes, synaptosomes were incubated for 1 h at room temperature with the following antibodies: donkey anti-rabbit AlexaFluor-488 and goat anti-guinea pig AlexaFluor-633 (1:1000 both, confocal analysis aimed at identifying co-localization of mGlu 3 receptor and VGLUT1 proteins), with donkey anti-mouse AlexaFluor-488 and goat anti guinea pig AlexaFluor-633 (1:1000 both, confocal analysis aimed at identifying co-localization of mGlu 2 receptor and VGLUT1 proteins), with donkey anti-rabbit AlexaFluor-488 with goat anti-mouse AlexaFluor-633 (1:1000 both, confocal analysis aimed at identifying co-localization of mGlu 2 and mGlu 3 receptor proteins). Synaptosomes were then applied to coverslips (Musante et al., 2008a) . Fluorescence images (512 × 512 × 8 bit) were then visualized by use of a sixchannel Leica TCS SP5 laser-scanning confocal microscope, equipped with 458, 476, 488, 514, 543 and 633 nm excitation lines, through a plan-apochromatic oil immersion objective 63X/1.4NA. Light collection configuration was optimized according to the combination of chosen fluorochromes. Sequential channel acquisition was performed to avoid crosstalk. A Leica 'LAS AF' software package was used for image acquisition, storage and visualization. The quantitative estimation of co-localized proteins was performed as described previously (Musante et al., 2008a; Summa et al., 2013) , by calculating the 'co-localization coefficients' (Manders et al., 1993) . They express the fraction of colocalizing molecular species in each component of a dualcolour image and are based on the Pearson's correlation coefficient, a standard procedure for matching one image with another in pattern recognition. If two molecular species are co-localized, the overlay of their spatial distributions has a correlation value higher than what would be expected by chance alone. Costes et al. (2004) developed an automated procedure to evaluate the correlation between the green and red channels with a significance level >95%. The same procedure automatically determines an intensity threshold for each colour channel based on a linear least-square fit of the green and red intensities in the image's 2D correlation cytofluorogramme. Costes's approach was carried out by macro routines integrated as plugins (WCIF Colocalization Plugins, Wright Cell Imaging Facility, Toronto Western Research Institute, Canada) in the ImageJ 1.51p software (Wayne Rasband, NIH, USA).
Calculations and statistical analysis
Sigma plot 10 data analysis and graphing software package were used for data handling/statistics and for graph drawing. ANOVA was performed followed by Dunnett's test or Newman-Keuls multiple comparisons test, as appropriate; direct comparisons were performed by Student's t-test. Post hoc tests were done only if F value was significant. Data were considered significant if P < 0.05. Experiments were carried out to quantify the effects of antagonists alone and of pretreatment of the synaptosomes with antibodies on the KCl-evoked release of [ 3 H]-D-Asp. In accord with our previous results (Di Prisco et al., 2016a) and consistent with Curtis et al. (2015) , at least n = 5 replicates were carried out for each experimental condition. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology. org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 .
Results
Effects of LY566332 and of LY2389575 on the LY379268-induced inhibition of [ 3 H]-D-Asp exocytosis from cortical glutamatergic synaptosomes
Purified synaptosomes isolated from the cortex of adult male mice were preloaded with [
3 H]-D-Asp and exposed to a mild (12 mM KCl) depolarizing stimulus (Grilli et al., 2004; Di Prisco et al., 2012) in the absence or in the presence of the mGlu 2/3 receptor agonist LY379268. Previous studies showed that 3 nM LY379268 causes a significant, submaximal, inhibition of the Effects of the mGlu 2 PAM LY566332 and of the mGlu 3 NAM LY2389575 on the inhibition of the 12 mM KCl-evoked [ 3 H]-D-Asp overflow elicited by the mGlu 2/3 agonist LY379268 in mouse cortical synaptosomes. The 12 mM KCl-evoked release of tritium over the basal release amounted to 1.39 ± 0.36 nCi. Results are expressed as a percentage of the 12 mM KCl-evoked tritium overflow (% of control). Data are the mean ± SEM of n (number within brackets) experiments. * P < 0.05 versus the 12 mM KCl-evoked tritium overflow;°P < 0.05 versus the 12 mM KCl/1 μM LY566332-evoked tritium overflow; # P < 0.05 versus the 12 mM KCl/3 nM LY379268-evoked tritium overflow; § P < 0.05 versus the 12 mM KCl/10 nM LY379268-evoked tritium overflow.
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LY379268-mediated inhibition of the 12 mM KCl-evoked (Figure 2 ; see also Di 2016a) . LY566332 (0.1-1 μM) failed to significantly modify the 30 pM LY379268-induced inhibition of tritium exocytosis (Figure 2 ). Experiments were performed to investigate the impact of this compound on the tritium release evoked by 15 mM KCl in the presence of a lower (1 pM) concentration of the mGlu 2/3 agonist. Again, the mGlu2 PAM was devoid of activity ( Figure 2) . However, the inhibitory effect elicited by LY379268 (30 pM) was totally abolished when LY2389575 (1 μM) was added concomitantly (Figure 2 and from mGlu2/3 À/À mice (Figure 4 ). Both receptor antibodies recognized proteins with a mass of about 100 kDa in the brain homogenates from the mice belonging to the four different strains. In particular, the anti-mGlu 3 antibody recognized a band at 100 kDa largely conserved in the four lysates ( Figure 4B ), consistent with the presence of non-specific immunoreactivity. In contrast, the band at about 100 kDa recognized by the anti-mGlu 2 antibody has a higher intensity in the WT and in the mGlu3 À/À lysates when compared to mGlu2 À/À and mGlu2/3 À/À lysates, suggesting the presence of a monomeric form of the mGlu 2 receptor protein ( Figure 4A ). 
Presynaptic mGlu 2/3 autoreceptor subtypes BJP
Immunochemical studies showed that the anti-mGlu 2 receptor antibody recognized a clear mGlu 2 immunoreactivity in the lysates of the synaptosomes from the cortex of WT mice at about 200 kDa, which is consistent with the presence of the dimeric form of the receptor ( Figure 5A ). Also mGlu 2 immunopositivity was detectable, although to a lesser extent, in spinal cord synaptosomal lysates ( Figure 5B ). The antimGlu 3 antibody recognized a band with an apparent mass of about 200 kDa in both cortical and spinal cord synaptosomal lysates ( Figure 5A,B) . mGlu 2 and mGlu 3 receptor proteins co-localize with VGLUT1 protein in mouse cortical and spinal cord synaptosomes Confocal microscopy was carried out to investigate whether mGlu 2 and mGlu 3 receptors co-localize with VGLUT1, here used as a selective marker of glutamate terminals. A diffuse mGlu 2 -immunoreactivity ( Figure 6A , green) was observed in VGLUT1-positive ( Figure 6B , red) cortical synaptosomes ( Figure 6C , yellow, merge, 91 ± 4%, n = 12). The mouse cortical synaptosomal preparation also showed a significant colocalization of mGlu 3 receptors and VGLUT1 (Figure 6D , green; E, red; F, yellow, merge, 74 ± 4%, n = 12). Finally, a significant percentage of mGlu 2 positive particles ( Figure 6G , green) was also reactive for mGlu 3 receptors (Figure 6H , red; I, yellow, merge, 83 ± 4%, n = 12), while the expression of mGlu 2 immunoreactivity in mGlu 3 receptor-positive particles was less pronounced ( Figure 6I , yellow, merge 71 ± 3%, n = 12).
In spinal cord synaptosomes, mGlu 2 receptor immunoreactivity ( Figure 7A , green) and mGlu 3 receptor immunoreactivity ( Figure 7D , green) were observed in VGLUT1-immunopositive ( Figure 7B ,E, red) particles ( Figure 7C , yellow, merge, 55.7 ± 3.1 of mGlu 2 receptor localization in VGLUT1-positive cells; Figure 7F , yellow, merge, 46.5 ± 7.2 of mGlu 3 receptor localization in VGLUT1-positive cells). Finally, mGlu 3 receptor immunopositive particles showed a low immunoreactivity for mGlu 2 receptor signalling ( Figure 7I , merge, yellow, 33.1 ± 6.2 of mGlu 2 receptor immunoreactivity in mGlu 3 receptor immunoreactive particles), while a larger co-localization of mGlu 3 receptor immunosignal with mGlu 2 receptor-positive particles was detected ( Figure 7I , 1.10 ± 0.6, n = 10, results expressed as induced overflow; mean ± SEM) but totally abolished the LY379268-induced inhibition of the radioactive overflow (Figure 8) . Similarly, incubation of cortical synaptosomes with the anti-mGlu 3 receptor antibody did not significantly modify the 12 mM KCl-evoked tritium exocytosis (synaptosomes incubated with anti-mGlu 3 receptor antibody: 1.11 ± 0.7, n = 8, results expressed as induced overflow; mean ± SEM). In contrast, LY379268 (3 nM) still significantly inhibited the 12 mM KCl-evoked release of tritium from cortical synaptosomes pre-exposed to the antimGlu 3 receptor antibody, although the inhibitory effect was significantly less pronounced that that observed in control synaptosomes (Figure 8 ). modified in synaptosomes pre-exposed to the anti-mGlu 2 receptor antibody, but it was significantly abolished in synaptosomes pre-exposed to the anti-mGlu 3 receptor antibody ( Figure 9 ).
Discussion
Since the 90s, novel ligands for the group II mGlu receptors have been synthesized and their activity characterized. These compounds are typified by selectivity and by nanomolar affinities for these receptors and might represent the prototype of new neuroprotective agents (Nickols and Conn, 2014; Yin and Niswender, 2014) . The novel compounds include ligands displaying mixed agonist/antagonist pharmacological effects on both mGlu 2 and mGlu 3 receptors, The highly conserved sequence of the two receptor proteins makes it difficult to compare the pharmacological profile of these mixed agents, in terms of affinity, activity and efficacy at each receptor subtype, and also to identify selective native neuronal and glial systems to be used as cellular models for their pharmacological characterization (but see Schoepp, 2001; Hanna et al., 2013; Sanger et al., 2013; Durand et al., 2014) . We used new molecules and established compounds to characterize the pharmacological profile of native mGlu 2/3 autoreceptors in cortical and spinal cord terminals. We recently proposed that these native autoreceptors belong to different receptor subtypes, having a different receptor composition and pharmacological profile, and might, therefore, provide native receptor models for studying the Figure 5 Western blot analysis reveals the presence of mGlu 2 receptor and mGlu 3 receptor protein dimers in mouse cortical (A) and spinal cord (B) synaptosomes (10 μg protein for cortical lysates and 20 μg protein for spinal cord lysates). The figure shows a representative blot of five (cortex) to seven (spinal cord) analyses carried out on different days. pharmacological profile of new drugs (Di Prisco et al., 2016a ). This conclusion is now further supported by the functional and immunochemical studies described in the present work.
As a first approach, we focussed on two novel allosteric modulators able to discriminate between mGlu 2 and mGlu 3 receptors: the mGlu 2 receptor PAM LY566332 and the mGlu 3 receptor NAM LY2389575. It is known that PAMs preferentially amplify receptor-mediated events elicited by submaximal concentrations of orthosteric agonists, while NAMs impede receptor-mediated events regardless of the amount of agonist applied. To study the impact of PAM and NAM, mGlu 2/3 receptor-mediated inhibition of glutamate exocytosis was elicited by exposing synaptosomes to concentrations of LY379268 that assure the submaximal activation of both of the two autoreceptors. When choosing the LY379268 concentrations to inhibit glutamate exocytosis from the two synaptosomal preparations, we took into consideration the strikingly different potency (about 4 order of magnitude) of LY379268 in cerebral cortex when compared to spinal cord synaptosomes highlighted in our previous study (Di Prisco et al., 2016a) . A molecular explanation of this striking difference is not yet available, and future studies will be required to address this aspect. We found that LY566332 amplified the inhibitory activity of LY379268 at presynaptic cortical autoreceptors, leaving unchanged the LY379268-mediated effect in spinal cord terminals. In spinal cord synaptosomes, the positive allosteric effects of LY566332 could not be revealed even if the mGlu 2/3 agonist was present at a lower concentration, further confirming that the mGlu 2 receptor subtype does not participate in the LY379268-mediated inhibition of glutamate exocytosis in these terminals. In contrast, LY2389575 significantly recovered the inhibitory activity exerted by LY379268 at spinal cord mGlu 3 -preferring autoreceptors, while it slightly, although not significantly, modified the efficacy of a submaximal amount of LY379268 at presynaptic mGlu 2 -preferring autoreceptors in cortical synaptosomes. The antagonist-like activity of the mGlu 3 NAM, however, was disclosed when cortical synaptosomes were exposed to a concentration of LY379268 eliciting the Figure 6 Confocal analysis of mGlu 2 and mGlu 3 receptor immunoreactivities in glutamatergic VGLUT1-positive cortical nerve terminals: co-localization of the two receptor proteins. The figure shows representative images of six independent experiments carried out on different days. almost maximal inhibitory effect at these terminals. Comparable results were obtained when studying the impact of the mGlu 2 PAM BINA and the mGlu 3 NAM ML337. Altogether, these observations largely corroborated the hypothesis that mGlu 3 receptor subtypes account for presynaptic control of glutamate exocytosis from spinal cord terminals, while both mGlu 2 and mGlu 3 receptors participate in the control of glutamate overflow from cortical terminals.
To further support the data obtained with group II NAMs and PAMs, we approached the pharmacological characterization of these receptors by using selective anti-mGlu 2 and antimGlu 3 receptor antibodies as receptor ligands. Classically, antibodies have been used to characterize the subunit composition of receptors in immunochemical studies. More recently, these reagents were proposed as tools to define the pharmacological profile of receptors, in particular GPCRs (Gupta et al., 2008; Musante et al., 2008b and references therein, Di Prisco et al., 2012 , 2016b Merega et al., 2015) . Actually, the binding of an antibody to the ligand-binding pocket of the receptor or to its extraterminal region(s) causes either activation and/or blockade of the receptor-mediated functions, mimicking the effect of an agonist or antagonist at these structures (Musante et al., 2008b; Di Prisco et al., 2012) .
Antibodies raised against the extracellular epitope of the mGlu receptors have different effects on the LY379268-mediated inhibition of glutamate exocytosis in the two synaptosomal preparations. In particular, the anti-mGlu 2 receptor antibody impeded the inhibitory activity of LY379268 on glutamate exocytosis in cortical synaptosomes, but not in spinal cord terminals.Whereas, the LY379268-induced inhibition of glutamate exocytosis was impeded by the anti-mGlu 3 receptor antibody in spinal cord synaptosomes, and it was slightly, although significantly, reduced in cortical terminals pretreated with the antibody.
Before drawing any conclusions from these findings, these observations deserve some brief comments. Firstly, the possibility that antibody cross-reactivity might affect our results is excluded on the basis of the high selectivity of the two antibodies, revealed in the Western blot analysis carried out with cortical homogenates from mGlu 2 and/or mGlu 3 
Figure 7
Confocal analysis highlighting the presence of mGlu 2 and mGlu 3 receptor immunoreactivities in glutamatergic spinal cord VGLUT1-positive nerve terminals: co-localization of the two receptor proteins. The figure shows representative images of eight independent experiments carried out on different days.
receptor knockout mice. In our previous studies, we demonstrated that incubation of synaptosomes with antibodies raised against cytosolic proteins (i.e. β actin) did not affect the spontaneous and the K + -evoked release of glutamate from both cortical and spinal cord terminals, ruling out the possibility that unspecific events might account for the effects observed (Musante et al., 2008b; Di Prisco et al., 2012; Merega et al., 2015) . Secondly, the fact that both antibodies failed to modify on their own the KCl-evoked glutamate exocytosis in both synaptosomal preparations allows us to rule out the occurrence of unspecific effects and also suggest that the antibodies do not mimic mGlu 2/3 receptor agonist(s) and/or PAM(s) at mGlu 2/3 receptors. Rather, our results indicate that antibodies preferentially act as selective antagonist and/or NAM at these targets. Finally, even if monoclonal antibodies are thought to be the best candidates as receptor agonists/antagonists, our results demonstrate that polyclonal antibodies can also be applied to function as receptor agonists or antagonists (reviewed by Gupta et al., 2008) . Notably, the results obtained with the two antibodies were superimposable on those obtained with selective PAM and NAM and suggest that in spinal cord terminals, mGlu 3 -preferring autoreceptors are pivotal for LY379268-induced inhibition of glutamate exocytosis, while in cortical synaptosomes, mGlu 2 autoreceptors play the main role, although the mGlu 3 receptors also participate in this effect. Quite interestingly, the use of the selective antibodies in immunochemical analysis unveiled a scenario well in line with the functional conclusions from release studies. In fact, Western blot analysis revealed the presence of both antimGlu 2 and anti-mGlu 3 receptor immunoreactivities in cortical (see also Ferraguti and Shigemoto, 2006) and spinal cord synaptosomal lysates; this is compatible with the idea that synaptosomal particles originating from both CNS regions are endowed with the two mGlu receptor proteins. These results, however, do not provide information on where the receptors are located (i.e. on glutamatergic or nonglutamatergic spinal cord terminals). This conclusion is proposed on the basis of the results obtained with confocal microscopy, which was carried out to highlight the co-localization of anti-mGlu 2 and anti-mGlu 3 receptor immunoreactivities with VGLUT1, used here as a selective marker of the glutamatergic particles.
Confocal analysis suggested that within the cortical synaptosomal preparations, there are glutamatergic synaptosomes endowed with group II mGlu receptors containing the mGlu 2 receptor protein and synaptosomes possessing group II mGlu receptors containing the mGlu 3 receptor protein. Here, the high co-localization of mGlu 2 positivity with VGLUT1 when compared to mGlu 3 receptor indicates the predominant expression of mGlu 2 receptors in these terminals. However, the high co-localization of mGlu 3 receptor reactivity with the mGlu 2 receptor-positive particles suggests that most of the cortical glutamatergic terminals possessing mGlu 2 -preferring autoreceptors also express co-localized mGlu 3 receptors. In contrast in the spinal chord, the largest population of glutamatergic terminals was endowed with mGlu 3 receptors, but mGlu 3 immunopositivity (i.e. of the receptor that shows the largest distribution in glutamatergic terminals) slightly co-localized with the less diffuse mGlu 2 receptor immunoreactivity, suggesting that most of the spinal cord terminals do not possess both receptor proteins.
As a whole, based on both the functional and nonfunctional observations described here, we confirm our versus the 12 mM KCl-evoked tritium overflow from control cortical synaptosomes;°P < 0.05 versus the 12 mM KCl/3 nM LY379268-evoked tritium overflow from control cortical synaptosomes; # P < 0.05 versus the 12 mM KCl-evoked tritium overflow from cortical synaptosomes incubated with the anti-mGlu 3 receptor antibody; § P < 0.05 versus the 12 mM KCl/3 nM LY379268-evoked tritium overflow from control cortical synaptosomes.
Figure 9
Effects of the incubation of spinal cord synaptosomes with antimGlu 2 receptor or anti-mGlu 3 
